# Acute Respiratory Failure â€“ Clinical Call Protocol

**Guidelines Referenced:**  
American Thoracic Society/European Respiratory Society Clinical Practice Guidelines for Acute Respiratory Failure 2017, British Thoracic Society Guidelines for Non-Invasive Ventilation in Acute Respiratory Failure 2016, GOLD Global Strategy for COPD 2023

**Official Sources:**  
https://www.atsjournals.org/doi/10.1164/rccm.201610-2058ST  
https://www.brit-thoracic.org.uk/quality-improvement/guidelines/emergency-oxygen/  
https://goldcopd.org/2023-gold-report-2/

## CARD INTERFACE LAYOUT

### Card 0 â€“ Dynamic Action Card (Node Dependent)

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ACUTE RESPIRATORY FAILURE                                   â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“± CALLED BY: Step-down RN, Bed 14                         â”‚
â”‚ Patient: 71yo F with COPD, increased work of breathing      â”‚
â”‚                                                           â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”                        â”‚
â”‚ â”‚     IMMEDIATE ACTIONS           â”‚                        â”‚
â”‚ â”‚ â˜‘ High-flow O2 started          â”‚ [15L NRB â†’ SpO2 90%]   â”‚
â”‚ â”‚ â˜‘ ABG sent                      â”‚ [Results below]        â”‚
â”‚ â”‚ â˜‘ CXR ordered portable          â”‚ [Pending]              â”‚
â”‚ â”‚ â˜‘ RT at bedside                â”‚ [BiPAP setup ready]    â”‚
â”‚ â”‚ â˜ BiPAP trial started          â”‚ [Consider based on ABG] â”‚
â”‚ â”‚ â˜ Intubation kit ready         â”‚ [If NIV fails]         â”‚
â”‚ â”‚                                â”‚                        â”‚
â”‚ â”‚ Bronchodilators: Continuous albuterolâ”‚                   â”‚
â”‚ â”‚ Steroids: Methylpred 125mg IV   â”‚                        â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜                        â”‚
â”‚                                                           â”‚
â”‚ VITALS: BP 158/92, HR 112, RR 32, SpO2 90% on 15L, T 37.9Â°Câ”‚
â”‚                                                           â”‚
â”‚ ABG RESULTS:                                               â”‚
â”‚ â€¢ pH: 7.22 (acidotic)  â€¢ PaCO2: 78 (â†‘â†‘)                   â”‚
â”‚ â€¢ PaO2: 58 (hypoxemic) â€¢ HCO3: 30 (compensated)           â”‚
â”‚                                                           â”‚
â”‚ ğŸš¨ TYPE II RESPIRATORY FAILURE                             â”‚
â”‚ Acute on chronic hypercapnia - BiPAP candidate             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**Example - BiPAP Management Node:**

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ BiPAP TRIAL INITIATED                                       â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ CURRENT SETTINGS:                                          â”‚
â”‚ IPAP: 14 cmH2O | EPAP: 6 cmH2O | FiO2: 60% | Rate: 12     â”‚
â”‚                                                           â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”                        â”‚
â”‚ â”‚     30-MINUTE ASSESSMENT        â”‚                        â”‚
â”‚ â”‚                                â”‚                        â”‚
â”‚ â”‚ IMPROVEMENT NOTED:              â”‚                        â”‚
â”‚ â”‚ â€¢ RR: 32 â†’ 24 (â†“ 8/min) âœ“      â”‚ [Target <25]           â”‚
â”‚ â”‚ â€¢ SpO2: 84% â†’ 91% âœ“            â”‚ [Target 88-92%]        â”‚
â”‚ â”‚ â€¢ Accessory muscle use: â†“       â”‚ [Less prominent]       â”‚
â”‚ â”‚ â€¢ Speaking: 2-3 â†’ 5-6 words     â”‚ [Improved]             â”‚
â”‚ â”‚                                â”‚                        â”‚
â”‚ â”‚ PATIENT TOLERANCE:              â”‚                        â”‚
â”‚ â”‚ â€¢ Mask seal: Good               â”‚ [No air leaks]         â”‚
â”‚ â”‚ â€¢ Comfort: 7/10                 â”‚ [Acceptable]           â”‚
â”‚ â”‚ â€¢ Synchrony: Good               â”‚ [No fighting vent]     â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜                        â”‚
â”‚                                                           â”‚
â”‚ REPEAT ABG IN 1 HOUR:                                      â”‚
â”‚ Expect: pH >7.30, PaCO2 <70, improved oxygenation         â”‚
â”‚                                                           â”‚
â”‚ SUCCESS CRITERIA:                                          â”‚
â”‚ â€¢ pH >7.30 within 2 hours                                 â”‚
â”‚ â€¢ RR <25, improved mental status                           â”‚
â”‚ â€¢ SpO2 88-92% on reduced FiO2                             â”‚
â”‚                                                           â”‚
â”‚ âš ï¸ FAILURE â†’ Prepare for intubation                        â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### Card 1 â€“ Static Assessment/Types & Causes

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ RESPIRATORY FAILURE TYPES & CAUSES                         â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ TYPE I (HYPOXEMIC FAILURE):                                â”‚
â”‚ â€¢ PaO2 <60 mmHg on room air                                â”‚
â”‚ â€¢ Normal or low PaCO2                                       â”‚
â”‚ â€¢ V/Q mismatch or shunt physiology                         â”‚
â”‚ â€¢ Causes: Pneumonia, ARDS, pulmonary edema, PE, atelectasisâ”‚
â”‚                                                           â”‚
â”‚ TYPE II (HYPERCAPNIC FAILURE):                             â”‚
â”‚ â€¢ PaCO2 >45 mmHg with pH <7.35                             â”‚
â”‚ â€¢ Â± Hypoxemia                                              â”‚
â”‚ â€¢ Ventilatory pump failure                                 â”‚
â”‚ â€¢ Causes: COPD exacerbation, severe asthma, neuromuscular, â”‚
â”‚   overdose, chest wall deformity                          â”‚
â”‚                                                           â”‚
â”‚ MIXED TYPE:                                                â”‚
â”‚ â€¢ Both hypoxemia + hypercapnia                             â”‚
â”‚ â€¢ Severe pneumonia, ARDS, end-stage lung disease          â”‚
â”‚                                                           â”‚
â”‚ WORK OF BREATHING ASSESSMENT:                              â”‚
â”‚ â€¢ RR >30/min, accessory muscle use, tripod positioning     â”‚
â”‚ â€¢ Paradoxical breathing, speaking ability (<5 words)       â”‚
â”‚ â€¢ Mental status: Confusion (hypoxia), somnolence (CO2)     â”‚
â”‚                                                           â”‚
â”‚ P/F RATIO (PaO2/FiO2):                                     â”‚
â”‚ â€¢ >300: Normal  â€¢ 200-300: Mild ARDS                      â”‚
â”‚ â€¢ 100-200: Moderate ARDS  â€¢ <100: Severe ARDS             â”‚
â”‚                                                           â”‚
â”‚ PRECIPITATING FACTORS:                                     â”‚
â”‚ â€¢ Infection (pneumonia, sepsis)                           â”‚
â”‚ â€¢ Heart failure exacerbation                              â”‚
â”‚ â€¢ Medication non-compliance                                â”‚
â”‚ â€¢ Environmental factors (pollution, allergens)             â”‚
â”‚                                                           â”‚
â”‚ RED FLAGS: pH <7.25, altered mental status, hemodynamic    â”‚
â”‚ instability, inability to protect airway, cardiac arrest   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### Card 2 â€“ Static Physical Exam/Medications

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ PHYSICAL EXAM & MEDICATIONS                                 â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ FOCUSED EXAMINATION:                                       â”‚
â”‚ â€¢ Vitals: RR >30, SpO2 <90%, tachycardia, hypertension     â”‚
â”‚ â€¢ General: Accessory muscle use, tripod position, cyanosis  â”‚
â”‚ â€¢ Pulmonary: Wheeze (COPD), rales (CHF), decreased sounds   â”‚
â”‚ â€¢ Cardiac: S3 gallop, irregular rhythm, JVD                â”‚
â”‚ â€¢ Neurologic: Confusion, somnolence, asterixis             â”‚
â”‚                                                           â”‚
â”‚ ğŸ’¨ OXYGEN DELIVERY SYSTEMS:                                â”‚
â”‚ Target SpO2: 88-92% (COPD), >92% (non-COPD)               â”‚
â”‚ â€¢ Nasal cannula: 1-6L/min (FiO2 24-44%)                   â”‚
â”‚ â€¢ Simple mask: 5-10L/min (FiO2 35-60%)                    â”‚
â”‚ â€¢ Non-rebreather: 15L/min (FiO2 85-95%)                   â”‚
â”‚ â€¢ High-flow nasal cannula: Up to 60L/min, heated/humidifiedâ”‚
â”‚                                                           â”‚
â”‚ ğŸ’¨ NON-INVASIVE VENTILATION:                               â”‚
â”‚ BiPAP Indications: COPD/CHF exacerbation, pH 7.25-7.35,   â”‚
â”‚ cooperative patient, intact airway reflexes                â”‚
â”‚ Initial settings: IPAP 10-12, EPAP 5, FiO2 100% then wean â”‚
â”‚ Contraindications: Altered mental status, vomiting risk,   â”‚
â”‚ facial trauma, hemodynamic instability                     â”‚
â”‚                                                           â”‚
â”‚ ğŸ’Š PHARMACOLOGIC TREATMENT:                                â”‚
â”‚ â€¢ Bronchodilators: Albuterol 2.5-5mg nebx3, then q20min   â”‚
â”‚   Ipratropium 0.5mg neb q6h, consider continuous albuterol â”‚
â”‚ â€¢ Corticosteroids: Methylprednisolone 125mg IV q6h or      â”‚
â”‚   Prednisone 40-60mg PO daily x 5 days                    â”‚
â”‚ â€¢ Antibiotics: If bacterial infection suspected            â”‚
â”‚   (Azithromycin 500mg + Ceftriaxone 1g IV)                â”‚
â”‚                                                           â”‚
â”‚ INTUBATION CRITERIA:                                       â”‚
â”‚ Failed NIV trial, pH <7.25, altered mental status,        â”‚
â”‚ respiratory arrest, inability to protect airway            â”‚
â”‚                                                           â”‚
â”‚ LINK TO RSI PROTOCOL: Seamless transition if NIV fails     â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

## FLOWCHART (Bottom Panel â€“ Mermaid Algorithm)

```mermaid
graph TD
    A[Respiratory Distress Recognition]
    B[O2 plus ABG & Assess WOB]
    C{Type of Failure?}
    D[High-flow O2 & Treat Underlying Cause]
    E[Consider NIV for COPD/CHF]
    F{NIV Candidate?}
    G[BiPAP Trial 1-2 hours]
    H[Prepare for Intubation]
    I{Improving on O2?}
    J[Continue Current & Monitor]
    K[Escalate Support & Consider NIV]
    L{Response to NIV?}
    M[Continue NIV & Wean FiO2]
    N[RSI & Mechanical Ventilation]
    O[Transition to Lower Support]

    A --> B
    B --> C
    C -- "Type I" --> D
    C -- "Type II" --> E
    E --> F
    F -- Yes --> G
    F -- No --> H
    D --> I
    I -- Yes --> J
    I -- No --> K
    G --> L
    L -- Good --> M
    L -- Poor --> H
    H --> N
    M --> O
    J --> O
    K --> G
```

## INTERACTIVE ELEMENTS

### ABG Quick Interpreter
```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚         ABG RAPID ANALYSIS              â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ pH: [7.22]     (7.35-7.45)             â”‚
â”‚ PaCO2: [78]    (35-45 mmHg)            â”‚
â”‚ PaO2: [58]     (80-100 mmHg)           â”‚
â”‚ HCO3: [30]     (22-28 mEq/L)           â”‚
â”‚ SaO2: [87]%    (>95%)                  â”‚
â”‚                                         â”‚
â”‚ PRIMARY DISORDER:                       â”‚
â”‚ ğŸ”´ Respiratory Acidosis                 â”‚
â”‚                                         â”‚
â”‚ COMPENSATION:                           â”‚
â”‚ Partial metabolic compensation          â”‚
â”‚ Expected HCO3: 29-31 (actual: 30) âœ“    â”‚
â”‚                                         â”‚
â”‚ OXYGENATION STATUS:                     â”‚
â”‚ Hypoxemia - moderate                    â”‚
â”‚ P/F Ratio: 97 (severe, on 60% FiO2)    â”‚
â”‚ A-a Gradient: 45 (elevated)            â”‚
â”‚                                         â”‚
â”‚ INTERPRETATION:                         â”‚
â”‚ â†’ Acute on chronic Type II failure      â”‚
â”‚ â†’ COPD exacerbation likely              â”‚
â”‚ â†’ BiPAP candidate                       â”‚
â”‚                                         â”‚
â”‚ [CALCULATE P/F] [TREND VALUES]          â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### BiPAP Optimization Guide
```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚      BiPAP SETTINGS OPTIMIZER           â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ CURRENT SETTINGS:                       â”‚
â”‚ IPAP: 14 cmH2O [â–²â–¼ Adjust]             â”‚
â”‚ EPAP: 6 cmH2O  [â–²â–¼ Adjust]             â”‚
â”‚ FiO2: 60%      [â–²â–¼ Titrate]            â”‚
â”‚ Backup Rate: 12/min                     â”‚
â”‚                                         â”‚
â”‚ PATIENT RESPONSE (30 min):              â”‚
â”‚ â€¢ RR: 32 â†’ 24 âœ“ Improving               â”‚
â”‚ â€¢ SpO2: 84% â†’ 91% âœ“ Target range        â”‚
â”‚ â€¢ Mental status: Alert                  â”‚
â”‚ â€¢ Mask tolerance: Good                  â”‚
â”‚                                         â”‚
â”‚ RECOMMENDATIONS:                        â”‚
â”‚ âœ“ Current settings appropriate          â”‚
â”‚ â€¢ Wean FiO2 to 50% if SpO2 stable      â”‚
â”‚ â€¢ Recheck ABG in 1 hour                 â”‚
â”‚                                         â”‚
â”‚ ESCALATION CRITERIA:                    â”‚
â”‚ â€¢ pH <7.25 after 2 hours               â”‚
â”‚ â€¢ Worsening mental status               â”‚
â”‚ â€¢ Inability to maintain SpO2 >88%      â”‚
â”‚                                         â”‚
â”‚ SUCCESS MARKERS:                        â”‚
â”‚ pH >7.30, RR <25, improved comfort      â”‚
â”‚                                         â”‚
â”‚ [ADJUST SETTINGS] [RECHECK ABG]         â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### Intubation Decision Support
```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚     INTUBATION READINESS CHECKER        â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ CLINICAL INDICATIONS:                   â”‚
â”‚ â˜ pH <7.25 despite optimal NIV         â”‚
â”‚ â˜‘ Worsening mental status               â”‚
â”‚ â˜ Hemodynamic instability               â”‚
â”‚ â˜ Inability to protect airway           â”‚
â”‚ â˜ Respiratory arrest                    â”‚
â”‚                                         â”‚
â”‚ NIV TRIAL STATUS:                       â”‚
â”‚ Duration: 2 hours                       â”‚
â”‚ Response: Partial improvement            â”‚
â”‚ pH trend: 7.22 â†’ 7.28                   â”‚
â”‚ Mental status: Alert but anxious        â”‚
â”‚                                         â”‚
â”‚ EQUIPMENT READY:                        â”‚
â”‚ â˜‘ ETT 7.5 available                    â”‚
â”‚ â˜‘ RSI medications drawn                 â”‚
â”‚ â˜‘ BVM with PEEP valve                  â”‚
â”‚ â˜‘ Suction setup                        â”‚
â”‚                                         â”‚
â”‚ TEAM ASSEMBLY:                          â”‚
â”‚ â˜‘ Respiratory therapist present         â”‚
â”‚ â˜‘ Second provider available             â”‚
â”‚ â˜ Anesthesia backup called              â”‚
â”‚                                         â”‚
â”‚ RECOMMENDATION:                         â”‚
â”‚ Continue NIV trial x 1 more hour        â”‚
â”‚ If no improvement â†’ Proceed with RSI     â”‚
â”‚                                         â”‚
â”‚ [CONTINUE NIV] [PROCEED RSI] [CALL BACKUP]â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

## VIRTUA VOORHEES ACUTE RESPIRATORY FAILURE ADDENDA

- **Respiratory Therapy Services:** 24/7 RT coverage with BiPAP/CPAP expertise, high-flow nasal cannula capabilities, and ventilator management
- **RSI Protocol Integration:** Seamless transition to rapid sequence intubation if non-invasive ventilation fails
- **Critical Care Support:** ICU beds available for mechanical ventilation with pulmonology consultation via Transfer Center 856-886-5111
- **Quality Metrics:** Time to BiPAP initiation, non-invasive ventilation success rates, intubation avoidance, length of stay

## REFERENCE (GUIDELINE & SOURCE)
American Thoracic Society/European Respiratory Society Clinical Practice Guidelines for Acute Respiratory Failure 2017.  
https://www.atsjournals.org/doi/10.1164/rccm.201610-2058ST

**Additional References:**  
British Thoracic Society Guidelines for Non-Invasive Ventilation in Acute Respiratory Failure 2016  
https://www.brit-thoracic.org.uk/quality-improvement/guidelines/emergency-oxygen/

GOLD Global Strategy for Prevention, Diagnosis and Management of COPD 2023  
https://goldcopd.org/2023-gold-report-2/

Rochwerg B, et al. Official ERS/ATS Clinical Practice Guidelines: Non-invasive Ventilation for Acute Respiratory Failure. Eur Respir J. 2017.  
https://erj.ersjournals.com/content/50/2/1602426

**All steps follow current evidence-based guidelines for acute respiratory failure management with integrated ABG interpretation, BiPAP optimization protocols, and seamless transition to mechanical ventilation via RSI protocol when non-invasive approaches fail.**
